Home » Topics » BioWorld Science

BioWorld Science
RSS

SPNS2 inhibition may be useful in treating autoimmune disease

Aug. 10, 2021

NRx initiates phase IIb study of BriLife COVID-19 vaccine in Georgia

Aug. 10, 2021

Otsuka receives a grant for phase II study of OPC-167832 plus delamanid and bedaquiline

Aug. 10, 2021

Trillium initiates dosing of patients with TP53-mutated AML in phase Ib/II study of TTI-622

Aug. 10, 2021

Phase II MERIT study of AXS-05 achieves primary and key secondary endpoints

Aug. 10, 2021

Gruenenthal divulges glucocorticoid receptor modulators

Aug. 10, 2021

New PIN1 inhibitors discovered at Pimedbio, DGMIF

Aug. 10, 2021

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine patent ATR kinase inhibitors

Aug. 10, 2021

Korea Institute of Science and Technology identifies TNK2/MAP4K2 inhibitors

Aug. 10, 2021

First patient dosed in phase Ib/II study of AVB-500 in pancreatic adenocarcinoma

Aug. 10, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...